You can read Premium News stories in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
27 September 2019
Regulatory agencies around the world are taking action on medicines containing ranitidine after tests showed some contain "low levels" of a probable human carcinogen called N-nitrosodimethylamine (NDMA).
23 September 2019
Advisers to the US Food and Drug Administration (FDA) have recommended that GlaxoSmithKline (GSK) Consumer Healthcare's nicotine oral spray can be marketed as an OTC product.
20 August 2019
GlaxoSmithKline (GSK) Consumer Healthcare is seeking to extend its range of OTC nicotine-replacement therapy (NRT) products in the US with a nicotine oral spray.
23 July 2019
Sanofi has gained exclusive OTC rights to Roche's Tamiflu (oseltamivir) for prevention and treatment of flu in the US.
1 July 2019
Alliance Pharma, Pfizer and the German Medicines Manufacturers' Association, the BAH, have all recently announced people changes.
7 June 2019
The US Food and Drug Administration (FDA) needs to "step up very quickly" with regulation for cannabidiol (CBD) products, says Scott Melville, president and chief executive officer of the US Consumer Healthcare Products Association (CHPA). According to Melville, the current situation in the US is li...
9 April 2019
The US Food and Drug Administration (FDA) is holding a public hearing on potential ways of regulating products containing cannabis and cannabis-derived compounds including cannabidiol (CBD).
5 March 2019
Scott Gottlieb has resigned as commissioner of the US Food and Drug Administration (FDA) just two years after he was appointed to the post.
14 February 2019
The Food and Drug Administration (FDA) plans to strengthen the regulation of dietary supplements in the US. The regulatory agency describes the move as "one of the most significant modernisations of dietary supplements regulation and oversight in more than 25 years".
21 January 2019
The US Food and Drug Administration (FDA) is making "unprecedented new efforts" to support the switch of naloxone from prescription to OTC status.